Jyothi Nagajyothi

Dr. Jyothi Nagajyothi


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2019 in mBio
Verified
Journal Article
Open access
PDF file
JAJaneesh Plakkal Ayyappan
Janeesh Plakkal Ayyappan
UGUsha Ganapathi
Usha Ganapathi
KLKezia Lizardo
Kezia Lizardo
CVChristopher Vinnard
Christopher Vinnard
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
JNJyothi Nagajyothi
Jyothi Nagajyothi
Although the lungs are the port of entry and the predominant site of TB disease manifestation, we and others have demonstrated that M. tuberculosis also persists in adipose tissue of aerosol-infected animals and directly or indirectly alters adipose tissue physiology, which in turn alters whole-body immuno-metabolic homeostasis. Our present report demonstrates a direct effect of loss of adipocytes (fat cells) on promoting the severity of pulmonary pathogenesis during TB, advancing our understanding of the pathogenic interactions between wasting and TB activation/reactivation.

16 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NONeelam Oswal
Neelam Oswal
KLKezia Lizardo
Kezia Lizardo
DDDhanya Dhanyalayam
Dhanya Dhanyalayam
JAJANEESH PLAKKAL AYYAPPAN
JANEESH PLAKKAL AYYAPPAN
HTHariprasad Thangavel
Hariprasad Thangavel
JNJyothi Nagajyothi
Jyothi Nagajyothi
Tuberculosis (TB) is a highly infectious bacterial disease that primarily attacks the lungs. TB is manifested either as latent TB infection (LTBI) or active TB disease, the latter posing a greater threat to life. The risk of developing active TB disease from LTBI is three times higher in individuals with type 2 diabetes mellitus (T2DM). The association between TB and T2DM is becoming more prominent as T2DM is rapidly increasing in settings where TB is endemic. T2DM is a chronic metabolic disorder characterized by elevated blood glucose, insulin resistance, and relative insulin deficiency. Insulin resistance and stress-induced hyperglycemia have been shown to be increased by TB and to return to normal upon treatment. Previously, we demonstrated that adipocytes (or fat tissue) regulate pulmonary pathology, inflammation, and Mycobacterium tuberculosis (Mtb) load in a murine model of TB. Metabolic disturbances of adipose tissue and/or adipocyte dysfunction contribute to the pathogenesis of T2DM. Thus, pathological adipocytes not only regulate pulmonary pathology, but also increase the risk for T2DM during TB infection. However, the cellular and molecular mechanisms driving the interaction between hyperglycemia, T2DM and TB remain poorly understood. Here, we report the impact of Mtb infection on the development of insulin resistance in mice fed on a regular diet (RD) versus high-fat diet (HFD) and, conversely, the effect of hyperglycemia on pulmonary pathogenesis in juvenile and adult mouse models. Overall, our study demonstrated that Mtb persists in adipose tissue and that Mtb infection induces irregular adipocyte lipolysis and loss of fat cells via different pathways in RD- and HFD-fed mice. In RD-fed mice, the levels of TNFα and HSL (hormone sensitive lipase) play an important role whereas in HFD-fed mice, ATGL (adipose triglyceride lipase) plays a major role in regulating adipocyte lipolysis and apoptosis during Mtb infection in adult mice. We also showed that Mtb infected adult mice that were fed an RD developed insulin resistance similar to infected adult mice that were overweight due to a HFD diet. Importantly, we found that a consequence of Mtb infection was increased lipid accumulation in the lungs, which altered cellular energy metabolism by inhibiting major energy signaling pathways such as insulin, AMPK and mToR. Thus, an altered balance between lipid metabolism and glucose metabolism in adipose tissue and other organs including the lungs may be an important component of the link between Mtb infection and subsequent metabolic syndrome.

1 February 2018 in Microbes and Infection
Verified
Journal Article
Closed access
JAJaneesh Plakkal Ayyappan
Janeesh Plakkal Ayyappan
CVChristopher Vinnard
Christopher Vinnard
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
JNJyothi Nagajyothi
Jyothi Nagajyothi

4 February 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JAJaneesh Plakkal Ayyappan
Janeesh Plakkal Ayyappan
KLKezia Lizardo
Kezia Lizardo
SWSean Wang
Sean Wang
EYEdward Yurkow
Edward Yurkow
JNJyothi Nagajyothi
Jyothi Nagajyothi
Background: Trypanosoma cruzi is an intracellular parasite that causes debilitating chronic Chagas cardiomyopathy ( CCM ), for which there is no effective drug or vaccine. Previously, we demonstrated increased cardiac lipid accumulation and endoplasmic reticulum stress in mice with CCM . Increased endoplasmic reticulum stress may lead to uncontrolled SREBP (sterol regulatory element‐binding protein) activation and lipotoxicity in the myocardium during the intermediate stage of infection and result in progression to chronic CCM . Therefore, we investigated whether inhibiting SREBP activation modulates CCM progression in T cruzi –infected mice. Methods and Results: T cruzi –infected cultured cardiomyocytes (3:1 multiplicity of infection; 24 hours postinfection) were incubated with betulin (3 μmol/L per mL), an SREBP inhibitor, for 24 hours. Quantitative polymerase chain reaction and Western blotting analyses demonstrated a significant reduction in SREBP activation, lipid biosynthesis, and endoplasmic reticulum stress in betulin‐treated infected cells compared with untreated cells. T cruzi infected (10 3 trypomastigotes of the Brazil strain) Swiss mice were fed a customized diet containing betulin during the intermediate stage (40 days postinfection) until the chronic stage (120 DPI ). Cardiac ultrasound imaging and histological and biochemical analyses demonstrated anatomical and functional improvements in betulin‐treated, infected mice compared with untreated controls: we observed a significant reduction in cholesterol/fatty acid synthesis that may result in the observed cardiac reduction in cardiac lipid accumulation, mitochondrial and endoplasmic reticulum stress, and ventricular enlargement. Conclusions: Our study (in vitro and vivo) demonstrates that inhibition of cardiac SREBP activation reduces cardiac damage during T cruzi infection and modulates CCM in a murine Chagas model.

7 April 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KLKezia Lizardo
Kezia Lizardo
JAJaneesh P. Ayyappan
Janeesh P. Ayyappan
NONeelam Oswal
Neelam Oswal
LWLouis M. Weiss
Louis M. Weiss
PSPhilipp E Scherer
Philipp E Scherer
JNJyothi Nagajyothi
Jyothi Nagajyothi
Chronic Chagas cardiomyopathy (CCC) caused by a parasiteTrypanosoma cruziis a life-threatening disease in Latin America, for which there is no effective drug or vaccine. The pathogenesis of CCC is complex and multifactorial. Previously, we demonstratedT.cruziinfected mice lose a significant amount of fat tissue which correlates with progression of CCC. Based on this an investigation was undertaken during both acute and chronicT.cruziinfection utilizing the FAT-ATTAC murine model (that allows modulation of fat mass) to understand the consequences of the loss of adipocytes in the regulation of cardiac parasite load, parasite persistence, inflammation, mitochondrial stress, ER stress, survival, CCC progression and CCC severity. Mice were infected intraperitoneally with 5x104and 103trypomastigotes to generate acute and chronic Chagas models, respectively. Ablation of adipocytes was carried out in uninfected and infected mice by treatment with AP21087 for 10 days starting at 15DPI (acute infection) and at 65DPI (indeterminate infection). During acute infection, cardiac ultrasound imaging, histological, and biochemical analyses demonstrated that fat ablation increased cardiac parasite load, cardiac pathology and right ventricular dilation and decreased survival. During chronic indeterminate infection ablation of fat cells increased cardiac pathology and caused bi-ventricular dilation. These data demonstrate that dysfunctional adipose tissue not only affects cardiac metabolism but also the inflammatory status, morphology and physiology of the myocardium and increases the risk of progression and severity of CCC in murine Chagas disease.

20 December 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
KLKezia Lizardo
Kezia Lizardo
JAJaneesh Plakkal Ayyappan
Janeesh Plakkal Ayyappan
UGUsha Ganapathi
Usha Ganapathi
WDWalderez O. Dutra
Walderez O. Dutra
Yunping QiuYunping Qiu
Yunping Qiu
JNJyothi Nagajyothi
Jyothi Nagajyothi
Chagas disease is caused by Trypanosoma cruzi which is endemic in Latin America. T. cruzi infection results in a latent infection with approximately a third of latently infected patients developing chronic Chagas cardiomyopathy (CCM). CCM is a common cause of cardiomyopathy in endemic regions and has a poor prognosis compared to other cardiomyopathies. The factors responsible for the transition from the asymptomatic indeterminate latent stage of infection to CCM are poorly understood. Our previous studies demonstrated that lipid metabolism and diet are important determinants of disease progression. In the present study, we analyzed various serum metabolomic biomarkers such as acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids in murine models of CCM, where the mice specifically develop either left or right ventricular cardiomyopathy based on the diets fed during the indeterminate stage in a murine model of Chagas disease. Our data provide new insights into the metabolic changes that may predispose patients to CCM and biomarkers that may help predict the risk of developing cardiomyopathy from T. cruzi infection. Author Summary. Chronic Chagas cardiomyopathy (CCM) is a parasitic disease prevalent in Latin America. Currently, no effective drugs or vaccines are available to prevent or cure CCM. The factors involved in the disease severity and progression are poorly understood to design new therapeutic interventions. In order to rapidly identify Chagas patients with a higher risk to develop CCM, a new set of biomarkers specific to Chagas disease is needed. We performed serum metabolomic analyses in chronic T. cruzi-infected mice fed on different diets and identified cardiac ventricular-specific metabolite biomarkers that could define CCM severity. In this paper, we present the results of serum metabolomic analyses and discuss its correlations to the diet-induced metabolic regulations in the pathogenesis of CCM in a murine model of Chagas disease.